PPT-Check and Checkmate

When the king is being attacked directly by an opponents piece we say the king is in check Check You can CHOOSE one of three things A void Move the king to a square which is not being attacked by an enemy piece. O Box 2552 West57375eld NJ 07090 S SWENSON SON INC Electrical Contractors Since 1928 Name Company Name Address Town and State Phone Cell Phone eMail Address Generator Model Generator Price Accessories Numbers Accessory Price Sub Total Less 2 Sal P Indy Lovlier Linda Cormorant Shelter Strait Northern Dancer Victoria Regina Bold Hour Blissful Old Trieste Ridden in Thestars Vice Regent Excruciation Silver Train One O Seven 1994 CHESTNUT F Leanne S. Hawken, PhD. University of Utah. Carrie Akins & Lisa Alford. North Point High School. Waldorf, MD. Objectives. Describe ways to modify CICO to improve its effectiveness. Learn answers to frequently asked questions regarding CICO implementation. Created By Muneeb Ahmed. Chess Game Contents. The Four-Move Checkmate. The Two-Move Checkmate. 3D Chess Game. The Halloween Gambit. Légal’s Mate. The Fried Liver Attack. The Sodium Attack*. The Ammonia Attack*. Overview. What is CICO?. CICO= “Check In/Check Out”. The CICO program is a school-wide, check-in, check-out . prevention. program for students who are starting to engage in problem . behaviors. . . CheckMate 1. Leanne S. Hawken. , University of . Utah. Danielle Starkey. , Missouri, SWPBS. Ericka . Dixon. , Winfield Primary. Illinois PBIS Forum, . 2012. Overview . BEP/CICO . Principles. Where have we been and where are we going?. Basics for Beginners. BOARD SET-UP. The letters go across the board in front of you.. “White on right!” . Each player has a white square in their right corner.. BOARD SET-UP. Queens sit on their own color square.. Checkmate.uk.com is a division of Lockton Companies LLP with registered number OC353198 and registered address: The St Botolph Building, 138 Houndsditch, London, EC3A 7AG. Lockton Companies LLP is A eventsof. . nivolumab. and . docetaxel. in the . CheckMate. 017 and . CheckMate. 057 phase III NSCLC trials. . Kartik. . Venkatachalam. Intervista a Cesare . Gridelli. Background: Nivo, a PD-1 antibody, received FDA approval based on superior overall survival in metastatic squamous (SQ) and non-squamous (NSQ) NSCLC patients who have progressed on or after platinum-based doublet chemotherapy. The purpose of this study was to assess the frequency and associated costs of grade 2–4 AEs in the CheckMate 017 (SQ) and CheckMate 057 (NSQ) phase III pivotal trials of nivo vs doc in stage IIIB/IV NSCLC. Methods: Patient-level data from these two trials were utilized to estimate the frequency of TRAEs requiring management in the nivo and doc arms, including serious and non-serious TRAEs. Minimum follow-up for AE reporting at database lock was 12 months. Grade 3–4 AE costs by event were identified from Healthcare Cost and Utilization Project (HCUP) data in 2010, which were adjusted to reflect 2012-equivalent US costs. Healthcare utilization associated with grade 2 AEs was based on clinical opinion and costs were based on HCUP or other sources as appropriate. Results: In both trials, more TRAEs were observed with doc than with nivo (Table), and the cost of managing TRAEs was 15.8 and 10.7 times higher in the doc arm vs the nivo arm for the CheckMate 017 and CheckMate 057 trials, respectively. Patients in the doc arm incurred an additional $6,585 and $5,422 per patient in managing AEs compared with patients in the nivo arm in the above two trials, respectively. The total estimated costs of managing TRAEs during these trials are presented in the Table. Conclusions: Large estimated differences in costs were observed in managing TRAEs, favoring nivo in the CheckMate 017 and CheckMate 057 pivotal trials. The reduction in costs for managing AEs with the use of nivo should be considered when assessing the value of nivo in this patient population.. PB4L Schools. Rob Horner. University of Oregon. www.pbis.org. Goals. Define the logic and core features of Check-in/Check-out (CICO) as a Tier II intervention within the PB4L approach.. Provide empirical evidence supporting CICO, and practical examples from local schools.. 1899: Coley’s Toxin. 2016: PD-1 Inhibition. 2016: PD-1 Inhibition. Overview. Tumor Immunology Cycle. The Yin and Yang of Immune Escape. Cancer Is Highly . Immunosuppressive. T Cells Killing a Tumor Cell. Chris . Borgmeier. , PhD. Portland State University. cborgmei@pdx.edu. www.tier2pbis.pbworks.com. CICO Resources. CICO within School-wide PBIS. All specialized interventions are more effective, and more durable, if they are done with school-wide . 1. Leanne S. Hawken. , University of . Utah. Danielle Starkey. , Missouri, SWPBS. Ericka . Dixon. , Winfield Primary. Illinois PBIS Forum, . 2012. Overview . BEP/CICO . Principles. Where have we been and where are we going?.